Find Clinical Trials
Study of the effect of trimetazidine MR 35 mg (2 tabs/day) on the emergence of choroidal neovascularisation in age-related macular degeneration: a multicentre, randomised, double-blind, placebo-controlled, phase III study in 1100 patients treated for 3 to 5 years
Servier Protocol Code:
MC3-06790-001
Sponsor:
Institut de Recherches Internationales Servier (I.R.I.S)
Find a recruiting site
Name:
Institut de Recherches Internationales Servier, Département des études cliniques
Phone number:
+33 1 55 72 60 00
Results
English (USA)Interventions / Treatments
The treatment(s) given to the participants in the study.
- Age related Macular Degeneration
- S006790
- TRIMETAZIDINE
Other study id numbers
Other identification numbers the study may be known by.
- MC3-06790-001